Exploring mechanism of occurrence and treatment of acute lung injury in mice based on GEO database and in vivo experiments
10.3969/j.issn.1000-484X.2025.11.001
- VernacularTitle:基于GEO数据库和体内实验探讨小鼠急性肺损伤发生机制与治疗方法
- Author:
Yonghu CHEN
1
;
Xilin WU
1
;
Zhe JIANG
1
;
Xuezheng LI
1
Author Information
1. 延边大学附属医院静脉用药调配中心,延边大学药学院,延吉 133002
- Publication Type:Journal Article
- Keywords:
GEO database;
Acute lung injury;
LPS;
NF-κB;
NLRP3
- From:
Chinese Journal of Immunology
2025;41(11):2561-2566
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To identify key genes involved in LPS-induced acute lung injury(ALI)using GEO database,to eluci-date its pathogenesis and discover potential therapeutic drugs.Methods:Gene expression data from LPS-induced ALI was collected by GEO database,and microbiotics online analysis platform was employed to identify differential expression genes,from which core genes were obtained.Metascape and DAVID were used for GO and KEGG enrichment analysis of these core genes to identify pathways associated with ALI.GSEA and protein interaction analysis were performed for these pathways for identification of core targets.Poten-tial therapeutic drug,kaempferol-3-O-α-L-(4″-E-p-coumaroyl)-rhamnoside(KAE)was validated by animal experiments.Results:Two GEO datasets were incorporated and 261 core genes with differential expression were identified.Data visualization indicated that LPS-induced ALI predominantly involved inflammatory pathways,such as TNF and NF-κB.In vivo validation was conducted in mice on two core targets within this pathway:NF-κB and NLRP3,potential therapeutic drug KAE was administered,which was found to mitigate LPS-induced lung tissue damage.Further investigations demonstrated that KAE could effectively improve ALI by reducing expressions of p-NF-κB,NLRP3 and other proteins.Conclusion:This study markes screening of LPS-induced ALI model within GEO database.Above findings reveal predominant involvement of NF-κB and NLRP3 within TNF and NF-κB signaling pathways in LPS-in-duced ALI.KAE has potential for ALI treatment by down-regulating expressions of p-NF-κB,NLRP3 and other proteins,expecting to be a candidate drug for ALI treatment.
